Amicus Therapeutics, Inc.
Case Summary

Case Details

Class Period:
March 19, 2015 – October 1, 2015
Date Filed:
October 8, 2015
Case Number:
District of New Jersey


The lawsuit, filed in Federal Court in the District of New Jersey, Lifestyle Investments, LLC v. Amicus Therapeutics, Inc., alleges that defendants issued a press release on September 15, 2015 in which they misrepresented that Amicus received positive news from a Pre-New Drug Application ("NDA") meeting with the Food and Drug Administration ("FDA") for its NDA for its oral small molecule pharmacological chaperone migalastat for the treatment of Fabry disease. Defendants publicly stated that, based on information provided by the FDA the NDA was on track for filing in the fourth quarter of 2015. Just two weeks later, however, on October 2, 2015, Amicus reversed course, stating that the FDA news was not positive and that it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Amicus' stock price plunged on this news, falling by 54% to $6.39 per share. Certain Amicus executives sold Amicus shares between September 15, 2015 and October 2, 2015.

Action Details

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us.

Saxena White

Copyright © 2006-2015, Saxena White P.A. All rights reserved.
Use of this site is governed by our Terms of Use Agreement and Privacy Policy. Legal Statement